PMID- 33253148
OWN - NLM
STAT- MEDLINE
DCOM- 20210122
LR  - 20210122
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Print)
IS  - 1935-2727 (Linking)
VI  - 14
IP  - 11
DP  - 2020 Nov
TI  - A community survey of coverage and adverse events following country-wide 
      triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 
      2018.
PG  - e0008854
LID - 10.1371/journal.pntd.0008854 [doi]
LID - e0008854
AB  - The Global Programme to Eliminate Lymphatic Filariasis has made considerable 
      progress but is experiencing challenges in meeting targets in some countries. 
      Recent World Health Organization guidelines have recommended two rounds of 
      triple-drug therapy with ivermectin, diethylcarbamazine (DEC), and albendazole 
      (IDA), in areas where mass drug administration (MDA) results with two drugs (DEC 
      and albendazole) have been suboptimal, as is the case in Samoa. In August 2018, 
      Samoa was the first country in the world to implement countrywide triple-drug 
      MDA. This paper aims to describe Samoa's experience with program coverage and 
      adverse events (AEs) in the first round of triple-drug MDA. We conducted a large 
      cross-sectional community survey to assess MDA awareness, reach, compliance, 
      coverage and AEs in September/October 2018, 7-11 weeks after the first round of 
      triple-drug MDA. In our sample of 4420 people aged >/=2 years (2.2% of the 
      population), age-adjusted estimates indicated that 89.0% of the eligible 
      population were offered MDA, 83.9% of the eligible population took MDA (program 
      coverage), and 80.2% of the total population took MDA (epidemiological coverage). 
      Overall, 83.8% (2986/3563) reported that they did not feel unwell at all after 
      taking MDA. Mild AEs (feeling unwell but able to do normal everyday things) were 
      reported by 13.3% (476/3563) and moderate or severe AEs (feeling unwell and being 
      unable to do normal everyday activities such as going to work or school) by 2.9% 
      (103/3563) of participants. This study following the 2018 triple-drug MDA in 
      Samoa demonstrated a high reported program awareness and reach of 90.8% and 
      89.0%, respectively. Age-adjusted program coverage of 83.9% of the total 
      population showed that MDA was well accepted and well tolerated by the community.
FAU - Willis, Gabriela A
AU  - Willis GA
AUID- ORCID: 0000-0002-2508-412X
AD  - Research School of Population Health, Australian National University, Canberra, 
      Australia.
FAU - Mayfield, Helen J
AU  - Mayfield HJ
AUID- ORCID: 0000-0003-3462-4324
AD  - Research School of Population Health, Australian National University, Canberra, 
      Australia.
FAU - Kearns, Therese
AU  - Kearns T
AUID- ORCID: 0000-0003-0862-7572
AD  - Menzies School of Health Research, Charles Darwin University, Brisbane, 
      Australia.
FAU - Naseri, Take
AU  - Naseri T
AD  - Ministry of Health, Apia, Samoa.
FAU - Thomsen, Robert
AU  - Thomsen R
AD  - Ministry of Health, Apia, Samoa.
FAU - Gass, Katherine
AU  - Gass K
AUID- ORCID: 0000-0002-2084-8039
AD  - Neglected Tropical Diseases Support Center, The Task Force for Global Heath, 
      Atlanta, Georgia, United States of America.
FAU - Sheridan, Sarah
AU  - Sheridan S
AD  - School of Public Health and Community Medicine, University of New South Wales, 
      Sydney, Australia.
FAU - Graves, Patricia M
AU  - Graves PM
AUID- ORCID: 0000-0002-5215-3901
AD  - College of Public Health, Medical and Veterinary Sciences, James Cook University, 
      Cairns, Australia.
FAU - Lau, Colleen L
AU  - Lau CL
AUID- ORCID: 0000-0001-8288-4169
AD  - Research School of Population Health, Australian National University, Canberra, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20201130
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Filaricides)
RN  - 70288-86-7 (Ivermectin)
RN  - F4216019LN (Albendazole)
RN  - V867Q8X3ZD (Diethylcarbamazine)
SB  - IM
MH  - Albendazole/administration & dosage/adverse effects
MH  - Animals
MH  - Diethylcarbamazine/administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Elephantiasis, Filarial/*drug therapy/prevention & control
MH  - Female
MH  - Filaricides/*administration & dosage/*adverse effects
MH  - Humans
MH  - Ivermectin/administration & dosage/adverse effects
MH  - Male
MH  - Mass Drug Administration/adverse effects/*statistics & numerical data
MH  - Program Evaluation
MH  - Samoa
MH  - Wuchereria bancrofti/isolation & purification
PMC - PMC7728255
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/01 06:00
MHDA- 2021/01/23 06:00
PMCR- 2020/11/30
CRDT- 2020/11/30 17:12
PHST- 2020/03/02 00:00 [received]
PHST- 2020/09/28 00:00 [accepted]
PHST- 2020/12/10 00:00 [revised]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/01/23 06:00 [medline]
PHST- 2020/11/30 17:12 [entrez]
PHST- 2020/11/30 00:00 [pmc-release]
AID - PNTD-D-20-00342 [pii]
AID - 10.1371/journal.pntd.0008854 [doi]
PST - epublish
SO  - PLoS Negl Trop Dis. 2020 Nov 30;14(11):e0008854. doi: 
      10.1371/journal.pntd.0008854. eCollection 2020 Nov.